Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Tanesha Washington (NPI 1811532278)

Field	Value
Entity Type	Individual
Organization	Tanesha Washington
Address	246 Gay Rd
City	Gadsden
State	SC
ZIP	29052
Taxonomy	Family Nurse Practitioner
NPI Enumerated	November 8, 2019

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused practice: lifetime Medicare revenue is $2.8M while there is no Medicaid billing on file, so the provider operates as a single-payer (Medicare) revenue source in the available data. The absence of any Medicaid activity suggests the practice either does not participate in Medicaid or has not billed Medicaid under the enumerated NPI.

Revenue is highly concentrated in a small set of biologic and specialty drug J‑codes: the precomputed top-three concentration shows the top 3 Medicare codes by revenue account for 50.3% of this provider's total Medicare revenue. Those top three are J3245 ($495K, 17.9%), J2357 ($480.6K, 17.4%), and J3380 ($413.1K, 15.0%), indicating half of Medicare receipts come from a narrow set of high-cost injectable therapies.

The code mix indicates a practice model centered on specialty injectable and infusion therapies rather than routine primary care: high-revenue J‑codes include monoclonal antibodies and biologics such as J3245, J2357, J3380, J2350, and J0517, and administration/infusion CPTs (96365, 96366, 96413) are present across the top codes. This pattern is consistent with an outpatient infusion/injectable service line or a specialty clinic that bills both drug and infusion administration fees.

Competitive standing is mixed by code: for J2357 the provider ranks #34 of 581 providers nationally (94th percentile; notably above typical national volume), signaling a strong national presence for omalizumab injections. By contrast, J3245 ranks #80 of 225 (64th percentile; typical, unremarkable volume) and J3380 ranks #45 of 620 (93th percentile; typical, unremarkable volume), which together suggest national prominence for some drugs but otherwise moderate participation for other top biologics.

There are notable statistical outliers in administration volume: 96372 shows 757 claims, $9 avg paid/claim, $6.8K revenue and is labeled an "extreme outlier, far above typical national volume" at the 99th percentile. This indicates unusually high volume of per‑injection or per‑visit medication administration relative to peers and could reflect workflow or service‑line specialization in frequent outpatient injections.

Smaller but visible administration and chemotherapy-related service billing appears alongside drug codes, for example 96365 ($17.9K revenue, 496 claims) and 96413 ($16K revenue, 219 claims), both of which rank in high percentiles for national providers (96365 at the 95th percentile and 96413 at the 64th percentile). These administration fees, while modest relative to drug revenue, reinforce that the practice bills the full episode of care (drug plus infusion/administration).

Provider tenure is established but not long-term: the NPI was enumerated 2019-11-08 (~7 years ago), indicating several years of claim activity but a relatively recent entry compared with long-standing national providers. This tenure is sufficient to generate the reported multi‑hundred‑thousand-dollar drug revenues and high percentile ranks for selected codes.

Beyond the top three, the practice shows repeated use of multiple high-cost specialty agents (for example J2350 $346.8K, J0517 $213.8K, J0897 $200.9K), each contributing material portions of revenue. Together with the concentrated top-three share (50.3%), this suggests business risk is concentrated in continued access to and reimbursement for a relatively small set of specialty injectables.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3245	Injection, tildrakizumab, 1 mg	4,500	$110	$495K
J2357	Injection, omalizumab, 5 mg	16,020	$30	$480.6K
J3380	Injection, vedolizumab, intravenous, 1 mg	24,300	$20	$413.1K
J2350	Injection, ocrelizumab, 1 mg	10,200	$30	$346.8K
J0517	Injection, benralizumab, 1 mg	1,620	$130	$213.8K
J0897	Injection, denosumab, 1 mg	11,160	$20	$200.9K
J1306	Injection, inclisiran, 1 mg	17,890	$10	$161K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,370	$30	$139.6K
J2356	Injection, tezepelumab-ekko, 1 mg	9,660	$10	$135.2K
J9312	Injection, rituximab, 10 mg	1,750	$60	$105K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Tanesha Washington — 2 of 21 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2350	5	10	10,800	$40	$546.8K
J3245	6	20	3,800	$110	$435.3K
J3380	2	20	11,400	$20	$231K
J9312	19	20	2,340	$60	$193.7K
J2357	1	30	4,360	$30	$183.8K
J0517	4	20	1,100	$130	$180.6K
J2356	3	10	7,140	$10	$109.9K
J1745	12	50	3,250	$30	$107K
J1306	3	20	8,800	$10	$95.1K
J0897	32	250	2,400	$20	$91.2K

Showing 1–10 of 21

Tanesha Washington — Billing Profile & Reimbursement Data

Sign up for Tanesha Washington — Billing Profile & Reimbursement Data policy alerts

Tanesha Washington — Billing Profile & Reimbursement Data

Sign up for Tanesha Washington — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Frequently Asked Questions

References